VESELKA, Josef, Lothar FABER, Max LIEBREGTS, Robert COOPER, Jaroslav JANUSKA, Jan KREJČÍ, Thomas BARTEL, Maciej DABROWSKI, Peter Riis HANSEN, Vibeke Marie ALMAAS, Hubert SEGGEWISS, Dieter HORSTKOTTE, Radka ADLOVA, Henning BUNDGAARD, Jurriën ten BERG, Rodney Hilton STABLES and Morten Kvistholm JENSEN. Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry. Journal of the American Heart Association. Hoboken: Wiley-Blackwell, 2017, vol. 6, No 5, p. 1-6. ISSN 2047-9980. Available from: https://dx.doi.org/10.1161/JAHA.117.005735.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry
Authors VESELKA, Josef (203 Czech Republic), Lothar FABER (276 Germany), Max LIEBREGTS (528 Netherlands), Robert COOPER (826 United Kingdom of Great Britain and Northern Ireland), Jaroslav JANUSKA (203 Czech Republic), Jan KREJČÍ (203 Czech Republic, guarantor, belonging to the institution), Thomas BARTEL (40 Austria), Maciej DABROWSKI (616 Poland), Peter Riis HANSEN (208 Denmark), Vibeke Marie ALMAAS (578 Norway), Hubert SEGGEWISS (276 Germany), Dieter HORSTKOTTE (276 Germany), Radka ADLOVA (203 Czech Republic), Henning BUNDGAARD (208 Denmark), Jurriën ten BERG (528 Netherlands), Rodney Hilton STABLES (826 United Kingdom of Great Britain and Northern Ireland) and Morten Kvistholm JENSEN (208 Denmark).
Edition Journal of the American Heart Association, Hoboken, Wiley-Blackwell, 2017, 2047-9980.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 4.450
RIV identification code RIV/00216224:14110/17:00097297
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1161/JAHA.117.005735
UT WoS 000404098600056
Keywords in English ablation; hypertrophic cardiomyopathy; outcome
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 20/3/2018 13:59.
Abstract
Background-The long-term efficacy and safety of alcohol septal ablation (ASA) in patients with highly symptomatic hypertrophic obstructive cardiomyopathy has been demonstrated. The aim of this study was to evaluate the long-term outcomes of mildly symptomatic patients with hypertrophic obstructive cardiomyopathy treated with ASA. Methods and Results-We retrospectively evaluated consecutive patients enrolled in the Euro-ASA registry (1427 patients) and identified 161 patients (53 +/- 13 years; 27% women) who were mildly symptomatic (New York Heart Association [NYHA] class II) pre-ASA. The median (interquartile range) follow-up was 4.8 (1.7-8.5) years. The clinical outcome was assessed and compared with the age-and sex-matched general population. The 30-day mortality after ASA was 0.6% and the annual all-cause mortality rate was 1.7%, which was similar to the age-and sex-matched general population (P=0.62). A total of 141 (88%) patients had resting left ventricular outflow tract gradient at the last clinical checkup <= 30 mm Hg. Obstruction was reduced from 63 +/- 32 to 15 +/- 19 mm Hg (P<0.01), and the mean NYHA class decreased from 2.0 +/- 0 to 1.3 +/- 0.1 (P<0.01); 69%, 29%, and 2% of patients were in NYHA class I, II, and III at the last clinical checkup, respectively. Conclusions-Mildly symptomatic hypertrophic obstructive cardiomyopathy patients treated with ASA had sustained symptomatic and hemodynamic relief with a low risk of developing severe heart failure. Their survival is comparable to the general population.
PrintDisplayed: 24/4/2024 16:44